CS

Pavel Majer

mail pavel.majerinvalid-email-name@invalid-email-domainuochb.cas.cz
phone +420 220 183 125
Group leader
Drug Discovery
Pavel Majer Group
All publications

Latest publications

Discovery of tert-Butyl Ester Based 6-Diazo-5-oxo-L-norleucine Prodrugs for Enhanced Metabolic Stability and Tumor Delivery
K. Novotná L. Tenora E. Prchalová J. Paule J. Alt V. Veeravalli J. Lam Y. Wu I. Šnajdr S. Gori V. S. Mettu T. Tsukamoto P. Majer B. S. Slusher R. Rais
Journal of Medicinal Chemistry 66 (22): 15493–15510 (2023)
Go to the publication arrow
Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6)
L. Motlová I. Šnajdr Z. Kutil E. Andris J. Ptáček A. Novotná Z. Nováková B. Havlínová W. Tueckmantel H. Dráberová P. Majer M. Schutkowski A. Kozikowski L. Rulíšek C. Bařinka
ACS Chemical Biology 18 (7): 1594–1610 (2023)
Go to the publication arrow
The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma
A. Frejlachová R. Lencová A. Venhauerová M. Skaličková O. Uher V. Caisová P. Majer L. Tenora P. Hansen J. Chmelař J. Kopecký Z. Zhuang K. Pacák J. Zenka
International Immunopharmacology 118: 110150 (2023)
Go to the publication arrow
Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells
J. Ptáček I. Šnajdr J. Schimer Z. Kutil J. Mikešová P. Baranová B. Havlínová W. Tueckmantel P. Majer A. Kozikowski C. Bařinka
International Journal of Molecular Sciences 24 (5): 4720 (2023)
Go to the publication arrow